/ POZEN Fact Sheet /

POZEN Inc., headquartered in Chapel Hill, NC, is a progressive pharmaceutical company committed to transforming medicine that transforms lives. The Company seeks to change how the healthcare industry fills unmet medical needs with a unique business model that transcends many of the pitfalls of traditional drug development and commercialization. Since its founding in 1996, POZEN has successfully created novel pharmacologic agents primarily for pain and pain-related conditions by integrating existing drug therapies that result in superior patient outcomes.

The value of this unique approach has been proven with our success in gaining FDA approval of two self-invented products in two years – something that almost no other small pharmaceutical company has done. POZEN is positioned to become a model of success as a 21st century pharmaceutical company. There are three key elements to our transformation strategy: (1) Develop products that deliver benefits to customers; (2) Make those products affordable and accessible; and (3) Engage with customers in a meaningful but highly efficient way.

POZEN will apply the same cost-efficient, strategic in-source model used for product development to the commercialization of its pipeline products – the PA portfolio. This means that POZEN will look for strategic partners for many of the sales and marketing activities, while retaining control of the commercialization strategy and execution.

Product Candidates to be Self-Marketed

POZEN is now working to address the needs of millions of people in the U.S. who could benefit from aspirin therapy. POZEN is applying the proven science of integrated therapies to develop a family of products that reduces the gastrointestinal (GI) -toxicity issues associated with aspirin therapy. The PA products use the same proprietary technology proven in VIMOVO to provide coordinated release of a proton pump inhibitor (PPI) and aspirin.

The first candidate is **PA32540**. It is a coordinated-delivery tablet combining 40 mg immediate release omeprazole, a proton pump inhibitor (PPI), layered around pH-sensitive 325 mg aspirin. This novel, patented product is administered orally once a day and if approved will be indicated for use for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers. PA32540 entered Phase 3 in the fourth quarter of 2009, with POZEN targeting NDA submission sometime in 2012 and potential launch in late 2013 or early 2014.

The POZEN pipeline also includes earlier-stage work evaluating the application of aspirin combinations for pain and pain-related conditions.

Licensed Products

Treximet® (sumatriptan / naproxen sodium) is approved for the acute treatment of migraine attacks, with or without aura, in adults. For additional information visit www.treximet.com. POZEN and GlaxoSmithKline (GSK) partnered in the development of the product and GSK is responsible for commercialization. POZEN has ex-US rights to develop and market other triptan and NSAID combinations.

VIMOVO™ (naproxen / esomeprazole magnesium) delayed release tablets is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID associated gastric ulcers. For additional information visit www.vimovo.com. POZEN and AstraZeneca (AZ) partnered in the development of the product and AZ is responsible for commercialization.

Company Snapshot

Ticker Symbol: POZN
NASDAQ Stock Market

Founded: 1996

IPO: October 2000

Employees: 29

Web site: www.pozen.com

Key Employees:

John R. Plachetka, Pharm.D.
Chairman, President & CEO
Elizabeth A. Cermak, MBA
EVP, Chief Commercial Officer
John G. Fort, MD, MBA
Chief Medical Officer
William L. Hodges, CPA
Sr. VP, Chief Financial Officer
Gilda M. Thomas, JD
Sr. VP, General Counsel

Analyst Coverage:

BMO Capital Markets,
Robert Hazlett
Brean Murray Carret & Co.,
Jonathan Aschoff, Ph.D.
Jefferies & Company, Inc.,
Eun Yang, Ph.D.
Wells Fargo Advisors,
Michael Tong, Ph.D., CFA
Zacks Equity Research,
Jason Napodano, CFA

Corporate Headquarters:
1414 Raleigh Road, Suite 400
Chapel Hill, NC 27517
919-913-1030/Fax: 919-913-1039

Contact:
Stephanie Bonestell
Manager, Investor Relations &
Public Relations

For further information, visit
www.pozen.com